Synergistic effect of hyperforin and paclitaxel on growth inhibition, apoptotic mediator activation in MCF-7 human breast cancer cells

Barathan, Muttiah and Zulpa, Ahmad Khusairy and Mee Hoong, See and Vellasamy, Kumutha Malar and Vadivelu, Jamuna (2021) Synergistic effect of hyperforin and paclitaxel on growth inhibition, apoptotic mediator activation in MCF-7 human breast cancer cells. Journal of Taibah University for Science, 15 (1). pp. 918-927. ISSN 1658-3655, DOI https://doi.org/10.1080/16583655.2021.2010910.

Full text not available from this repository.
Official URL: https://doi.org/10.1080/16583655.2021.2010910

Abstract

The role of hyperforin in combination anticancer therapy remain unknown. In this study, several doses of combination treatment (paclitaxel and hyperforin) were introduced to the Michigan Cancer Foundation (MCF)-7 cell culture for 24 h. The effectiveness of the drug's combination effect was determined by the combination index (CI)followed by the anticancer effect through apoptosis, reactive oxygen species (ROS), lactate dehydrogenase (LDH) and caspase 8 assays. It was found that combined doses of paclitaxel (7, 6, 5, 4 mu g/mL) and doses of hyperforin (1, 2, 3 and 4 mu g/mL) enhanced synergistic growth inhibitory effect. (Hy: 4 mu g/mL & Pa: 4 mu g/mL) was selected as suitable dose with lowest CI and it significantly induced changes to MCF-7 cell morphology and led to apoptosis with increased in the high level of ROS, LDH and caspase 8 compared to singly treated hyperforin. This study provides the basis for elucidation of combination of hyperforin and paclitaxel on animal models.

Item Type: Article
Funders: Kementerian Sains, Teknologi dan Inovasi
Uncontrolled Keywords: Combination; Apoptosis; Breast cancer
Subjects: R Medicine > R Medicine (General)
Divisions: Faculty of Medicine
Depositing User: Ms. Juhaida Abd Rahim
Date Deposited: 18 Feb 2022 01:18
Last Modified: 18 Feb 2022 01:18
URI: http://eprints.um.edu.my/id/eprint/26209

Actions (login required)

View Item View Item